EP1536012A4 - Human antihuman interleukin-6 antibody and fragment of the antibody - Google Patents

Human antihuman interleukin-6 antibody and fragment of the antibody

Info

Publication number
EP1536012A4
EP1536012A4 EP03791369A EP03791369A EP1536012A4 EP 1536012 A4 EP1536012 A4 EP 1536012A4 EP 03791369 A EP03791369 A EP 03791369A EP 03791369 A EP03791369 A EP 03791369A EP 1536012 A4 EP1536012 A4 EP 1536012A4
Authority
EP
European Patent Office
Prior art keywords
antibody
fragment
human
human antihuman
interleukin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03791369A
Other languages
German (de)
French (fr)
Japanese (ja)
Other versions
EP1536012A1 (en
Inventor
Kazuhisa Sugimura
Kazuyuki Yoshizaki
Toshihiro Nakashima
Takumi Sasaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemo Sero Therapeutic Research Institute Kaketsuken
Original Assignee
Chemo Sero Therapeutic Research Institute Kaketsuken
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31972776&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1536012(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chemo Sero Therapeutic Research Institute Kaketsuken filed Critical Chemo Sero Therapeutic Research Institute Kaketsuken
Publication of EP1536012A1 publication Critical patent/EP1536012A1/en
Publication of EP1536012A4 publication Critical patent/EP1536012A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

It is intended to provide a substance efficacious in treating an immunopathy in which interleukin-6 (IL-6) participates. Using the phage antibody method, a human antihuman IL-6 antibody and a human antihuman IL-6 antibody fragment showing a high affinity for human IL-6 are obtained. The above antibody and antibody fragment are expected as being useful as remedies for inflammation and an immunopathy caused by IL-6.
EP03791369A 2002-08-30 2003-08-28 Human antihuman interleukin-6 antibody and fragment of the antibody Withdrawn EP1536012A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002253036 2002-08-30
JP2002253036 2002-08-30
PCT/JP2003/010923 WO2004020633A1 (en) 2002-08-30 2003-08-28 Human antihuman interleukin-6 antibody and fragment of the antibody

Publications (2)

Publication Number Publication Date
EP1536012A1 EP1536012A1 (en) 2005-06-01
EP1536012A4 true EP1536012A4 (en) 2006-03-08

Family

ID=31972776

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03791369A Withdrawn EP1536012A4 (en) 2002-08-30 2003-08-28 Human antihuman interleukin-6 antibody and fragment of the antibody

Country Status (8)

Country Link
US (1) US7482436B2 (en)
EP (1) EP1536012A4 (en)
JP (1) JP4463104B2 (en)
KR (1) KR20050058486A (en)
CN (1) CN1678744B (en)
AU (1) AU2003261787B2 (en)
CA (1) CA2496523A1 (en)
WO (1) WO2004020633A1 (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20061324A1 (en) 2005-04-29 2007-01-15 Centocor Inc ANTI-IL-6 ANTIBODIES, COMPOSITIONS, METHODS AND USES
EP2336181A1 (en) 2005-12-09 2011-06-22 UCB Pharma, S.A. Antibody molecules having specificity for human IL-6
MY159787A (en) * 2006-06-02 2017-01-31 Regeneron Pharma High affinity antibodies to human il-6 receptor
BRPI0715115A2 (en) 2006-08-03 2013-06-04 Vaccinex Inc isolated monoclonal antibody, isolated nucleic acid molecule, expression vector, host cell, methods for treating a disease, and for producing an isolated monoclonal antibody, use of isolated monoclonal antibody, and, pharmaceutical composition
US8414897B1 (en) 2006-10-02 2013-04-09 The Uab Research Foundation Pathway for Th-17 cell development and methods utilizing same
TW200831528A (en) 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
AU2007327096A1 (en) * 2006-11-30 2008-06-05 Astrazeneca Ab Antibodies specific for the complex of Interleukin-6 and the Interleukin-6 receptor
MX2009012493A (en) * 2007-05-21 2010-01-20 Alder Biopharmaceuticals Inc Novel rabbit antibody humanization methods and humanized rabbit antibodies.
SG183742A1 (en) 2007-05-21 2012-09-27 Alderbio Holdings Llc Antibodies to il-6 and use thereof
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US20090238825A1 (en) * 2007-05-21 2009-09-24 Kovacevich Brian R Novel rabbit antibody humanization methods and humanized rabbit antibodies
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
NZ581742A (en) 2007-06-08 2012-09-28 Biogen Idec Inc Biomarkers for predicting anti-tnf responsiveness or non-responsiveness
US20100203009A1 (en) * 2007-10-02 2010-08-12 The Uab Research Foundation Pathway for Th-17 Cell Development and Methods Utilizing Same
JP2011520898A (en) 2008-05-13 2011-07-21 ノビミューン エスアー Anti-IL-6 / IL-6R antibodies and methods for their use
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
AU2009313958B2 (en) * 2008-11-13 2015-09-10 Femta Pharmaceuticals, Inc. Humanized anti-IL-6 antibodies
US8323649B2 (en) * 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
CN102438653B (en) 2008-11-25 2019-04-23 奥尔德生物制药公司 Prevention or treatment cachexia, weakness, fatigue and/or fever IL-6 antagonist
US9452227B2 (en) * 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
MX2012005927A (en) 2009-11-24 2012-11-23 Alder Biopharmaceuticals Inc Antibodies to il-6 and use thereof.
WO2012071561A2 (en) 2010-11-23 2012-05-31 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of anemia
AU2012223449A1 (en) 2011-03-03 2013-05-02 Apexigen, Inc. Anti-IL-6 receptor antibodies and methods of use
US9234035B2 (en) 2012-10-22 2016-01-12 Fountain Biopharma Inc. Antibodies to interleukin-6
MX2018000778A (en) 2015-07-31 2018-08-15 Medimmune Ltd Methods for treating hepcidin-mediated disorders.
AU2018214554C1 (en) 2017-02-01 2022-12-15 Novo Nordisk A/S Treatment of diuretic resistance
JP7395479B2 (en) 2018-01-05 2023-12-11 ノヴォ ノルディスク アー／エス Methods of treating IL-6-mediated inflammation without immunosuppression
CN110283249A (en) * 2018-03-19 2019-09-27 江苏莱博德医疗科技有限公司 A kind of people's ScFv single-chain antibody of anti-interleukin 6
CA3108951A1 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
SG11202101779RA (en) 2018-08-30 2021-03-30 Hcw Biologics Inc Multi-chain chimeric polypeptides and uses thereof
US11672826B2 (en) 2018-08-30 2023-06-13 HCW Biologics, Inc. Methods of treating aging-related disorders
EP3962942A1 (en) 2019-05-01 2022-03-09 Novo Nordisk A/S Anti-il-6 antibody formulation
CA3143035A1 (en) 2019-06-21 2020-12-24 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
JP2023519106A (en) 2020-02-11 2023-05-10 エイチシーダブリュー バイオロジックス インコーポレイテッド CHROMATOGRAPHIC RESIN AND USES THEREOF
AU2021220196A1 (en) 2020-02-11 2022-08-04 HCW Biologics, Inc. Methods of activating regulatory T cells
EP4103601A2 (en) 2020-02-11 2022-12-21 HCW Biologics, Inc. Methods of treating age-related and inflammatory diseases
JP2023525495A (en) 2020-04-29 2023-06-16 エイチシーダブリュー バイオロジックス インコーポレイテッド Anti-CD26 proteins and methods of their use
WO2021247003A1 (en) 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
AU2021283199A1 (en) 2020-06-01 2023-01-05 Immunitybio, Inc. Methods of treating aging-related disorders
AU2023228683A1 (en) 2022-03-02 2024-09-19 Immunitybio, Inc. Method of treating pancreatic cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005105998A1 (en) * 2004-04-27 2005-11-10 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute HUMAN ANTIAMYLOID β PEPTIDE ANTIBODY AND ANTIBODY FRAGMENT THEREOF

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5959085A (en) * 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
PT1074268E (en) * 1998-03-17 2008-02-28 Chugai Pharmaceutical Co Ltd Preventives or remedies for inflammatory intestinal diseases containing il-6 receptor antagonist antibodies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005105998A1 (en) * 2004-04-27 2005-11-10 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute HUMAN ANTIAMYLOID β PEPTIDE ANTIBODY AND ANTIBODY FRAGMENT THEREOF

Also Published As

Publication number Publication date
CN1678744A (en) 2005-10-05
WO2004020633A1 (en) 2004-03-11
JPWO2004020633A1 (en) 2005-12-15
US7482436B2 (en) 2009-01-27
AU2003261787B2 (en) 2008-11-06
EP1536012A1 (en) 2005-06-01
KR20050058486A (en) 2005-06-16
CA2496523A1 (en) 2004-03-11
AU2003261787A1 (en) 2004-03-19
CN1678744B (en) 2010-05-26
US20060240012A1 (en) 2006-10-26
JP4463104B2 (en) 2010-05-12

Similar Documents

Publication Publication Date Title
EP1536012A4 (en) Human antihuman interleukin-6 antibody and fragment of the antibody
ZA200409186B (en) Specific antibodies to amyloid beta peptide, pahrmaceutical compositions and methods of use thereof.
ATE515514T1 (en) USES OF MAMMAL CYTOKINE IL-23 ; RELATED REAGENTS
TW200511444A (en) Strained-silicon-on-insulator single-and double-gate MOSFET and method for forming the same
EP2520311A3 (en) Method of treating hemolytic disease
EP2371859A3 (en) Treatment of TNF alpha related disorders
WO2005052000A3 (en) Anti-il-20 antibodies and binding partners and methods of using in inflammation
EE05015B1 (en) Payment terminal device for connecting the m-point device, payment scheme and method of payment procedure
IS7684A (en) New compounds, preparations and methods for the treatment of inflammatory diseases and conditions
EA201000496A1 (en) SUBSTITUTED MINOCYCLINE COMPOUND, METHOD FOR OBTAINING SUBSTITUTED MINOCYCLINE COMPOUNDS (OPTIONS)
WO2006003388A3 (en) Compositions and methods for treating inflammatory disorders
EP1562968A4 (en) Anti-il-6 antibodies, compositions, methods and uses
WO2005044807A3 (en) Benzoimidazole compounds
DK2168984T3 (en) Human antibodies that bind human IL-12 and methods for its production
BR0107762B1 (en) porous alveolar filter and method for its manufacture.
EA200600065A3 (en) HYDROPHOBIC COMPOSITION AND BULK MATERIALS, THEIR APPLICATION
EA200300464A1 (en) HUMAN LIFE
WO2005023185A3 (en) Pharmaceutical compositions and method of using levodopa and carbidopa
AU2003242831A1 (en) Method of testing components designed to perform real-time, high resource functions
NO20026128D0 (en) Gel-shaped fuel, process for its preparation and its use
AU2003247303A1 (en) Antisense compounds, methods and compositions for treating ngal-related inflammatory disorders
WO2002068476A3 (en) Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders
IL161040A0 (en) Spreadable compositions for topical use, an improved process of making same and methods of using same
WO2002064092A3 (en) Method for evaluating therapeutic efficacy
AU2002304242A1 (en) Method, apparatus and plant for manufacturing engine fuel

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050308

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

A4 Supplementary search report drawn up and despatched

Effective date: 20060124

17Q First examination report despatched

Effective date: 20081203

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130301